Back to School: How biopharma can reboot drug development. Access exclusive analysis here

FDA panel rejects ESA limit

An FDA advisory panel voted 14-5 against FDA's proposed label change for erythropoiesis stimulating agents (ESAs) to treat anemia associated with chronic renal failure, but the panel members did not

Read the full 308 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE